Viracta Therapeutics, Inc.
VIRXDelisted- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001061027
Viracta Therapeutics, Inc. was delisted in 2025; its insiders filed their last Form 4 on Nov 27, 2024; 32 institutions reported holding it in 13F filings for Q4 2024, worth $583.0K in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 32
- Q4 2024, −5 vs. previous quarter
- 13F value
- $583.0K
- Reported value at the end of Q4 2024
- Superinvestors holding
- 0
- At the end of Q4 2024
Superinvestors holding VIRX, Q4 2024
No superinvestor reported holding VIRX at the end of Q4 2024.
Latest insider trades
Open-market purchases and sales by Viracta Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 27, 2024 (view filing) | Feb 27 | Same day | Chevallard Daniel R.CFO and COO | SSale | −3.40K | $0.73 | −$2.49K | −3.2%102.3K after | |
| Dec 4, 2023 (view filing)4:54 PM ET | Nov 30-Dec 1 | 4 days | Rothera MarkPresident and CEO | PPurchase | +100.0K | $0.4936 | +$49.4K | New position100.0K after | 2 lots |
| Nov 28, 2023 (view filing) | Nov 28 | Same day | Chevallard Daniel R.CFO and COO | SSale | −3.72K | $0.50 | −$1.86K | −3.6%98.8K after | |
| Aug 29, 2023 (view filing) | Aug 28 | 1 day | Chevallard Daniel R.CFO and COO | SSale | −3.51K | $1.45 | −$5.09K | −3.5%95.7K after | |
| May 26, 2023 (view filing) | May 25 | 1 day | Chevallard Daniel R.CFO and COO | SSale | −3.63K | $1.42 | −$5.16K | −3.8%92.3K after | |
| Feb 28, 2023 (view filing) | Feb 27 | 1 day | Rojkjaer LisaChief Medical Officer | SSale | −2.16K | $1.68 | −$3.62K | −4.3%48.1K after | |
| Feb 28, 2023 (view filing) | Feb 27 | 1 day | Chevallard Daniel R.CFO and COO | SSale | −3.60K | $1.68 | −$6.05K | −3.9%89.0K after | |
| Nov 29, 2022 (view filing) | Nov 28 | 1 day | Chevallard Daniel R.CFO and COO | SSale | −3.53K | $2.72 | −$9.61K | −4.0%85.7K after | |
| Nov 29, 2022 (view filing) | Nov 28 | 1 day | Rojkjaer LisaChief Medical Officer | SSale | −2.12K | $2.72 | −$5.76K | −4.4%46.1K after | |
| Aug 29, 2022 (view filing) | Aug 26 | 3 days | Rojkjaer LisaChief Medical Officer | SSale | −2.19K | $4.01 | −$8.78K | −4.7%44.1K after |
Top 10 13F holders, Q4 2024
The largest institutional positions in Viracta Therapeutics, Inc. at the end of Q4 2024; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Citadel Advisors LLC | 1,626,258 | $261.7K | 0.00% | +106,018+7.0% | Added |
| Vanguard Group Inc | 289,174 | $46.6K | 0.00% | −665,311−69.7% | Reduced |
| Aisling Capital Management LP | 288,571 | $46.2K | 0.02% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 286,395 | $46.1K | 0.00% | +40,996+16.7% | Added |
| BlackRock, Inc. | 234,846 | $37.8K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 224,250 | $36.1K | 0.00% | −25,757−10.3% | Reduced |
| Virtu Financial LLC | 128,231 | $21.0K | 0.00% | +128,231 | New |
| UBS Group AG | 93,177 | $15.0K | 0.00% | +93,082+97,981.1% | Added |
| HRT Financial LP | 82,673 | $13.0K | 0.00% | −56,149−40.4% | Reduced |
| State Street Corp | 65,867 | $10.6K | 0.00% | 00.0% | Unchanged |